ABC | Volume 111, Nº3, September 2018

Original Article Radaelli et al Secondary dyslipidemia in obese children Arq Bras Cardiol. 2018; 111(3):356-361 26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. Erratum in: Lancet. 2005;366(9494):1358; Lancet. 2008;371(9630):2084. 27. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210(1):202-8. Erratum in: Atherosclerosis. 2010;212(2):704. 28. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781-90. 29. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6. 30. Clauss SB, Holmes KW, Hopkins P, Stein E, ChoM, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682-8. 31. Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, HounslowN, et al; PASCAL Study Group. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. J Pediatr. 2015;167(2):338-43. 32. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2010:95(9):673-80. 33. O’Gorman CS, O’Neill M, Conwell L. Considering statins for cholesterol- reduction inchildren if lifestyleanddietchangesdonot improvetheirhealth:a reviewoftherisksandbenefits.VascHealthRiskManag.2010Dec20;7:1-14. 34. NupponenM,PahkalaK,JuonalaM,MagnussenCG,NiinikoskiH,Rönnemaa T, et al. Metabolic syndrome from adolescence to early adulthood: effect of infancy-onsetdietarycounselingoflow-saturated-fat:thespecialturkucoronary risk factor intervention project (strip). Circulation. 2015;131(7):605-13. 35. Reiner Z. Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ Res. 2014;114(2):233-5. 36. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic reviewandmeta-analysis of statin therapy in childrenwith familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27(8):1803-10. 37. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2014 Jul 23;(7):CD006401. 38. Mitka M. Experts question recommendations for universal lipid screenings in children. JAMA. 2012;308(8):750-1. 39. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312(10):1055-7. 40. Braamskamp MJ, Kusters DM, Wiegman A, Avis HJ, Wijburg FA, Kastelein JJ, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemiawho had initiated statin therapy in childhood. Atherosclerosis. 2015;241(2):427-32. 360